Ephraim Heller
Ephraim Heller is an inventor and entrepreneur, and the current CEO of SynAgile Corporation.[1] SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went public[2] and was later sold to Abbott Labs for $1.2 billion.[3] He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a venture partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard. His father is the engineer Adam Heller.
Patents[edit]
Heller holds over 100 US patents, including patents on blood glucose monitors and photocatalytic materials.[4]
References[edit]
- ↑ "Synagile:Founders". synagile.com. Retrieved 2023-11-21.
- ↑ "THERASENSE INC, Form S-1, Filing Date Oct 11, 2000" (PDF). secdatabase.com. Archived from the original (PDF) on May 16, 2018. Retrieved May 15, 2018. Unknown parameter
|url-status=ignored (help) - ↑ "THE MARKETS: STOCKS & BONDS; Corporate Earnings Jitters Send Shares Modestly Lower". The New York Times. 14 January 2004. Archived from the original on 16 May 2018. Retrieved 19 February 2017. Unknown parameter
|url-status=ignored (help) - ↑ "%22heller%2C ephraim%22 - United States Patent and Trademark Office Search Results". Archived from the original on 2017-01-18. Retrieved 2012-01-26. Unknown parameter
|url-status=ignored (help)
External links[edit]
- Profile in Businessweek
- Abbott Labs: "In April 2004, Abbott announced it had completed the acquisition of TheraSense, a leader in developing blood glucose self-monitoring devices that require very small blood samples to deliver rapid test results".
- Abbott's Annual Report for Fiscal Year 2003 featured the acquisition of Therasense on its cover.
- New York Times, January 14, 2004: "A deal by Abbott Laboratories to buy TheraSense for $1.2 billion in cash to bolster its diabetes drugs sent TheraSense up 31 percent , gaining $6.34, to $26.64. Abbott rose 24 cents, to $44.43."
This article "Ephraim Heller" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Ephraim Heller. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
